Antibodies

21 Jan 2017 OncoMed Initiates Enrollment of Phase 1b Clinical Trial of Brontictuzumab for the Treatment of Metastatic Colorectal Cancer Patients
21 Jan 2017 Pamrevlumab Pancreatic Cancer Clinical Data Presented at ASCO 2017 Gastrointestinal Cancers Symposium
19 Jan 2017 Opdivo (nivolumab) Demonstrated Efficacy and Improved Survival in Patients with Previously Treated Advanced Gastric Cancer in a Randomized Phase 3 Study
19 Jan 2017 Final CIMZIA® (certolizumab pegol) Phase 3 Trial Meets Primary Efficacy Endpoint in Patients with Moderate-to-Severe Chronic Plaque Psoriasis
18 Jan 2017 Daiichi Sankyo Initiates Phase 1/2 Study of Novel Antibody Drug Conjugate U3-1402 in Patients with HER3-Positive Metastatic or Unresectable Breast Cancer
18 Jan 2017 Boehringer Ingelheim biosimilar candidate to Humira® accepted for EMA and FDA regulatory review
18 Jan 2017 AstraZeneca expands 1st-line lung cancer Immuno-Oncology programme opportunities
12 Jan 2017 TG Therapeutics Announces Completion of Enrollment and B-cell Depletion Data from Part 1 of Ongoing Phase 2 Multiple Sclerosis Study
12 Jan 2017 Bird Rock Bio Receives Approval to Start First in Human Clinical Trial for Namacizumab, Enters Into Agreement with GE Healthcare for Process Development and Scale-up to Provide Clinical Phase 2 cGMP Material, and Enters into a Collaboration and Option Agr
12 Jan 2017 U.S. FDA Accepts Biologics License Application (BLA) for Mylan and Biocon's Proposed Biosimilar Trastuzumab
12 Jan 2017 Visterra Doses First Patient in Phase 2a Trial for VIS410, its Monoclonal Antibody in Development for the Treatment of Hospitalized Patients with Influenza A
12 Jan 2017 Affimed Provides Update on NK-Cell Immuno-Oncology Platform
11 Jan 2017 Coherus BioSciences Announces Positive Topline 24-Week Treatment Phase Three Results for CHS-1420 (HUMIRA® Biosimilar Candidate) in Patients with Psoriasis
11 Jan 2017 Merck Receives FDA Acceptance of Supplemental Biologics License Application for KEYTRUDA® (pembrolizumab) in Combination with Chemotherapy for First-Line Treatment of Metastatic Non-Squamous Non-Small Cell Lung Cancer
10 Jan 2017 ThromboGenics Enrolls First Patients in Phase II Clinical Study Evaluating THR-317 (anti-PlGF) for Diabetic Macular Edema (DME)
09 Jan 2017 MabVax Therapeutics Files Investigational New Drug Application for Novel Radioimmunotherapy Agent MVT-1075
09 Jan 2017 Immunomedics Announces Antitumor Effect of Sacituzumab Govitecan (IMMU-132) in Triple-Negative Breast Cancer Can be Enhanced With DNA-Repair Inhibitors
09 Jan 2017 Alexion Submits U.S. and EU Applications Seeking Approval of Soliris(R) (Eculizumab) as a Treatment for Patients with Refractory Generalized Myasthenia Gravis (gMG)
09 Jan 2017 Incyte and Merck to Advance Clinical Development Program Investigating the Combination of Epacadostat with KEYTRUDA® (pembrolizumab)
09 Jan 2017 Kymab Expands Infectious Disease Programmes
09 Jan 2017 FDA Grants Genentech’s Cancer Immunotherapy TECENTRIQ® (Atezolizumab) Priority Review in Additional Type of Advanced Bladder Cancer
06 Jan 2017 Aridis Pharmaceuticals Reports Positive Clinical Data from Phase 1/2a Study of Human Monoclonal Antibody AR-301 for Treating Pneumonia
06 Jan 2017 FDA Approves Genentech’s Lucentis® (Ranibizumab Injection) for Myopic Choroidal Neovascularization
05 Jan 2017 Seattle Genetics Initiates Phase 1 Trial of SGN-CD352A for Patients with Relapsed or Refractory Multiple Myeloma
05 Jan 2017 Pfizer Announces Positive Top-Line Results from the Comparative REFLECTIONS B538-02 Study for PF-06410293, a Potential Biosimilar to Humira®1 (adalimumab)

La Merie Biologics

FREE Weekly News Bulletin

2016 Sales ofAntibodies & Proteins

New Product Alert

For La Merie Publishing

Top